Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,635,808
  • Shares Outstanding, K 22,203
  • Annual Sales, $ 180,130 K
  • Annual Income, $ -465,890 K
  • EBIT $ -425 M
  • EBITDA $ -422 M
  • 60-Month Beta -1.05
  • Price/Sales 37.00
  • Price/Cash Flow N/A
  • Price/Book 9.34

Options Overview Details

View History
  • Implied Volatility 63.21% ( +3.54%)
  • Historical Volatility 36.29%
  • IV Percentile 70%
  • IV Rank 41.43%
  • IV High 93.93% on 10/18/24
  • IV Low 41.48% on 08/19/24
  • Put/Call Vol Ratio 0.80
  • Today's Volume 285
  • Volume Avg (30-Day) 496
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 18,792
  • Open Int (30-Day) 19,117

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -3.64
  • Number of Estimates 7
  • High Estimate -2.39
  • Low Estimate -5.15
  • Prior Year -7.10
  • Growth Rate Est. (year over year) +48.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
275.00 +5.15%
on 06/18/25
314.22 -7.97%
on 06/27/25
+10.94 (+3.93%)
since 06/06/25
3-Month
265.00 +9.12%
on 05/27/25
349.00 -17.14%
on 05/01/25
-21.35 (-6.88%)
since 04/07/25
52-Week
200.63 +44.13%
on 10/23/24
377.46 -23.39%
on 02/26/25
+12.62 (+4.56%)
since 07/05/24

Most Recent Stories

More News
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffraâ„¢) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

MDGL : 289.17 (-3.25%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

MDGL : 289.17 (-3.25%)
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

MDGL : 289.17 (-3.25%)
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

VKTX : 27.51 (-2.41%)
MDGL : 289.17 (-3.25%)
LLY : 772.87 (-1.00%)
Madrigal Announces New Clinical Data Demonstrating Rezdiffraâ„¢ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

MDGL : 289.17 (-3.25%)
Madrigal: Q1 Earnings Snapshot

Madrigal: Q1 Earnings Snapshot

MDGL : 289.17 (-3.25%)
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

MDGL : 289.17 (-3.25%)
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

MDGL : 289.17 (-3.25%)
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

MDGL : 289.17 (-3.25%)
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

MDGL : 289.17 (-3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 310.43
2nd Resistance Point 304.12
1st Resistance Point 296.65
Last Price 289.17
1st Support Level 282.86
2nd Support Level 276.55
3rd Support Level 269.07

See More

52-Week High 377.46
Fibonacci 61.8% 309.91
Last Price 289.17
Fibonacci 50% 289.04
Fibonacci 38.2% 268.18
52-Week Low 200.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar